Table 3:
Radiation-absorbed doses of
188
Re-6D2 compared to tositumomab, ibritumomab tiuxetan, and normal organ tolerance TD 5/5 (cGy).
Liver
Kidneys
Bone marrow
Urine bladder wall
Tositumomab 81 mCi
246
588
195
192
Ibritumomab tiuxetan 30 mCi
533
11
144
100
188
Re-6D2 40–60 mCi
130
305
17
158
188
Re-6D2 Estimated 100 mCi
344
650
42
350
Normal Organ Tolerance
3000
2300
200
6500